[State of the art in chemoradiotherapy combinations and potential role in targeting therapy approaches in nonsmall cell lung cancer].
The preclinical rationale for chemoradiation was demonstrated. While chemoradiation allowed for improved outcome in nonsmall cell lung cancer patients, prognosis of patients remains particularly pejorative, encouraging major expansion of targeted therapies concurrently with radiotherapy. Thorough knowledge in biological mechanisms of oncogenesis permitted identifying new therapeutic targets, for which specific interactions allow pharmacological radiosensitivity modulation. Two modalities of EGFR inhibitors have been developed: monoclonal antibodies and tyrosin kinase inhibitors, which assessement remains at its beginning. Angiogenesis inhibition was also developed, illustrating the absolute necessity for careful clinical assessment. Drugs with multiple targets are becoming available and offer new optimization modalities for radiation therapy.
Chargari
C
C
Département de radiothérapie, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France.
Deutsch
E
E
Le Péchoux
C
C
Magné
N
N
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D042442:Vascular Endothelial Growth Factors; D066246:ErbB Receptors